MedTrace Logo

Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression

NCT06094907 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-05-08

No results posted yet for this study

Summary

This study aims to evaluate the acute and subacute effects of an inhaled N, N-Dimethyltryptamine (DMT) in patients with partial response in depression.

Conditions

  • Depressive Disorder
  • Depression, Unipolar

Interventions

DRUG

N,N-Dimethyltryptamine

DMT will be administered using a vaporizer device in an ascending fixed-order of 15mg and 60mg.

Sponsors & Collaborators

  • Universidade Federal do Rio Grande do Norte

    lead OTHER

Principal Investigators

  • Draulio Araujo, Ph.D · Universidade Federal do Rio Grande do Norte

  • Marcelo Falchi, M.D. · Universidade Federal do Rio Grande do Norte

  • Fernanda Palhano-Fontes, Ph.D · Universidade Federal do Rio Grande do Norte

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-09
Primary Completion
2024-01-15
Completion
2024-03-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06094907 on ClinicalTrials.gov